Diagnosis and Treatment of Multidrug-Resistant Tuberculosis.
10.3904/kjm.2015.88.5.509
- Author:
Tae Sun SHIM
1
Author Information
1. Division of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. shimts@amc.seoul.kr
- Publication Type:Review
- Keywords:
Multidrug-resistant tuberculosis;
Diagnosis;
Treatment
- MeSH:
Clofazimine;
Cycloserine;
Diagnosis*;
Drug Resistance;
Fluoroquinolones;
Kanamycin;
Levofloxacin;
Prothionamide;
Pyrazinamide;
Tuberculosis;
Tuberculosis, Multidrug-Resistant*;
World Health Organization
- From:Korean Journal of Medicine
2015;88(5):509-517
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Despite global efforts to control tuberculosis (TB), multidrug-resistant TB (MDR-TB) is still a serious problem worldwide. The diagnosis of MDR-TB is based on mycobacterial culture followed by drug susceptibility testing, with results available in weeks to months. This requirement calls for rapid direct tests, especially genotypic tests, in which specimens are amplified directly for the detection of MDR-TB. The treatment of MDR-TB is challenging because of the high toxicity of second-line drugs and the longer treatment duration required compared to drug-susceptible TB. The selection of drugs in MDR-TB is based on the treatment history, drug susceptibility results, and TB drug resistance patterns in each region. Recent World Health Organization guidelines recommend the use of at least four second-line drugs (i.e., a newer fluoroquinolone, an injectable agent, prothionamide, and cycloserine or para-aminosalicylic acid) in addition to pyrazinamide. Kanamycin is the initial choice of an injectable drug, and newer fluoroquinolones include levofloxacin and moxifloxacin. For extensively drug-resistant TB, group 5 drugs such as linezolid and clofazimine need to be included. New drugs such as delamanid and bedaquiline have recently been approved for treating MDR-TB and other agents with novel mechanisms of action that can be given for shorter durations (6-12 months) for MDR-TB are under investigation.
